Corporate News – Market Update on Cofco Biotechnology Co., Ltd.
Cofco Biotechnology Co., Ltd. (stock code 000930.SZ) reported a neutral trading day on Wednesday, 21 April 2026, with its share price unchanged for the 24‑hour period that concluded at 10:21 PM Central Europe. At the close, the stock was quoted at CNY 4.94 on the Shenzhen Stock Exchange, reflecting a trading volume of approximately CNY 113.7 million during the last 24 hours.
Trading and Valuation Metrics
| Item | Value |
|---|---|
| Current market capitalisation | CNY 9.20 billion |
| Outstanding shares | 1.90 billion |
| 24‑hour trading volume | CNY 113.7 million |
| 52‑week high | CNY 8.14 (16 March 2026) |
| 52‑week low | CNY 4.24 (30 June 2026) |
| 200‑day simple moving average | CNY 4.91 |
| Month‑to‑date performance | −8.69 % (since end‑of‑month) |
The stock’s current price sits just above its 200‑day moving average, suggesting a slight upward bias from a technical perspective. However, the month‑to‑date decline of nearly 9 % indicates that investors remain cautious amid broader market volatility.
Comparative Performance of Related Stocks
The trading behaviour of other constituents of the Shenzhen and Hong Kong markets offers context for Cofco’s performance:
| Stock | Code | 24‑hour change | Current price | Market capitalisation | P/E ratio |
|---|---|---|---|---|---|
| Tofflon Science & Technology | 300171.SZ | 0 % | CNY 14.07 | CNY 11 billion | 42.18 |
| China Bohai Bank –H | 9668.HK | +2.07 % | HKD 0.73 | HKD 12.9 billion | 2.30 |
| Wuxi Boton | 300031.SZ | 0 % | CNY 26.35 | CNY 11 billion | 42.41 |
| Beijing Jingneng Clean Energy | 0579.HK | −2.80 % | HKD 1.54 | HKD 12.9 billion | 4.74 |
| China Publishing & Media | 601949.SS | 0 % | CNY 5.86 | CNY 11 billion | 20.46 |
While some peers, such as China Bohai Bank –H, registered modest gains, several technology and manufacturing names remained flat or fell, mirroring the subdued sentiment observed in the STAR Market on 20 October. That day the STAR Market experienced a 30 billion‑yuan contraction in overall financing, a trend that may be influencing investor behaviour across the broader Chinese equity landscape.
Company Overview
COFCO Biotechnology Co., Ltd. is headquartered in Bengbu, China, and specializes in the production, processing, and distribution of agricultural and sideline products. Its product portfolio includes fuel ethanol, edible alcohol, starch and modified starch, starch sugar, citric acid, monosodium glutamate, polylactic acid, and related by‑products. The company markets its goods domestically through the Shenzhen Stock Exchange and internationally via its website (www.cofcotech.com ).
Outlook
Given the current trading flatness and the broader context of mixed financing activity in China’s STAR Market, investors may view Cofco Biotechnology as a moderately liquid but cautious play. The stock’s proximity to its 200‑day moving average and its recent 52‑week low could signal potential support levels, while the significant month‑to‑date decline may prompt reassessment of the company’s valuation relative to peers with higher price‑to‑earnings multiples.
For stakeholders monitoring the Chinese biotech and agro‑chemical sectors, the forthcoming quarterly earnings report will be critical in determining whether Cofco can reverse its recent decline and capitalize on its established supply chain and product diversification.
